Atrial Natriuretic Peptide Increases Urodilatin in the Circulation
Authors:
- Rose M. OvertonRORose M. Overton
- Mary BlankenshipMBMary Blankenship
- Michael T. McCormickMMMichael T. McCormick
- Douglas D. SchockenDSDouglas D. Schocken
- 6 May 1998
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 18 (3) , 204-213
Abstract
Background: Urodilatin is a 32-amino-acid (AA) peptide formed in the kidney. Methods: High-performance gel permeation chromatography and high-pressure liquid chromatography evaluation of plasma followed by sensitive urodilatin and atrial natriuretic peptide (ANP) assays revealed that urodilatin does circulate distinctly from ANP. Results: Urodilatin circulates at very low levels (i.e 9–12 pg/ml). Infusion of ANP increased the circulating concentration of urodilatin 135-fold (p < 0.001), suggesting that some of the effects of ANP may be mediated by urodilatin while long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide did not affect urodilatin in healthy humans (n = 30). Only ANP decreased the renal clearance of urodilatin (60–75%, p < 0.01). Urodilatin was metabolized into peptides smaller than 5 AAs as well as excreted intact into urine. Conclusion: Urodilatin circulates and is increased by ANP in humans.Keywords
This publication has 2 references indexed in Scilit: